Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1629 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Yuyan Lei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Xiangya School of Pharmaceutical Science, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Fasting, Olopatadine Hydrochloride, Food-Drug Interactions, Histamine H1 Antagonists. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Hunan Science and Technology Youth Talent Support Program, Science and Technology Innovation Program of Hunan Province.
Abstract (Originalsprache)
Olopatadine hydrochloride, a second‐generation selective histamine H1 receptor antagonist, is an effective anti‐allergic agent. This study evaluated the pharmacokinetics and bioequivalence of two olopatadine hydrochloride tablet formulations in healthy Chinese subjects under fasting (n = 24) and fed (n = 24) conditions. A single‐center, randomized, open‐label, single‐dose, two‐way crossover study was conducted, in which 48 subjects were randomized to receive 5 mg of the test or reference formulation, followed by a 7‐day washout period. Blood samples were collected at predefined intervals up to 24 h post‐dose, and olopatadine plasma concentrations were measured using a validated liquid chromatography‐tandem mass spectrometry method. The results demonstrated no significant differences in the pharmacokinetic profiles between the test and reference formulations under fasting or fed conditions. The 90% confidence intervals (CIs) for the ratio of geometric means of C max , AUC 0–t , and AUC 0–∞ of olopatadine hydrochloride under both conditions were within the bioequivalence range of 0.80–1.25. A high‐fat diet delayed olopatadine hydrochloride absorption, leading to a reduction in C max to approximately 60% of the fasting value and a decrease in AUC to 85%–90%. No serious adverse events occurred, and safety profiles were comparable between formulations. This research confirmed the bioequivalence and similar safety of the generic olopatadine hydrochloride tablets to the reference formulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Xiangya School of Pharmaceutical Science, Central South University, Changsha, China.
- Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, Changsha, China.
- Changsha Duxact Biotech Co., Ltd, Changsha, China.
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China.
- Changsha Phamark Data Technology Co., Ltd, Changsha, China.
Förderung
- Hunan Science and Technology Youth Talent Support Program
- Science and Technology Innovation Program of Hunan Province
Zitieren
APA
Lei, Y., Pei, F., Wu, Q., Xiong, G., Liu, F., Wang, X., Chen, L., Li, C., Zhou, L., Fang, Q., Chen, W., Ouyang, D., & Li, X. (2025). Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1629
Vancouver
Lei Y, Pei F, Wu Q, Xiong G, Liu F, Wang X, et al. Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1629
BibTeX
@article{Lei2025,
author = {Lei, Yuyan and Pei, Fang and Wu, Qingqi and Xiong, Guiling and Liu, Fengzhi and Wang, Xintong and Chen, Lulu and Li, Chao and Zhou, Ling and Fang, Qing and Chen, Weiming and Ouyang, Dongsheng and Li, Xiaohui},
title = {Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1629}
}
EUVIMED